C4 Therapeutics (CCCC) Long-Term Investments (2021 - 2026)

C4 Therapeutics' Long-Term Investments history runs 6 years deep, the most recent figure standing at $32.6 million for Q1 2026.

• In Q1 2026, Long-Term Investments rose 66.17% year-over-year to $32.6 million; the TTM figure through Mar 2026 stood at $32.6 million (up 66.17% YoY), while the FY2025 annual figure was $48.6 million, up 117.2% from the prior year.
• Long-Term Investments was $32.6 million for Q1 2026 at C4 Therapeutics, down from $48.6 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $130.5 million in Q1 2022 to a low of $7.9 million in Q3 2025.
• Historically, Long-Term Investments has averaged $40.4 million across 5 years, with a median of $31.6 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments soared 301.53% in 2022, then tumbled 78.44% in 2023.
• A 5-year view of Long-Term Investments shows it stood at $61.0 million in 2022, then plunged by 54.06% to $28.0 million in 2023, then dropped by 20.17% to $22.4 million in 2024, then soared by 117.2% to $48.6 million in 2025, then plunged by 32.87% to $32.6 million in 2026.
• The last three Long-Term Investments figures came in at $32.6 million (Q1 2026), $48.6 million (Q4 2025), and $7.9 million (Q3 2025), per Business Quant data.